Health News Releases

  • Today April 11
April 10, 15:35
Byondis Appoints Christoph Korpus, PhD, MBA as Chief Executive Officer
Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, announces today the appointment of Christoph Korpus, PhD, MBA, as Chief Executiv
April 09, 14:40
Interim Data From Two Ongoing Investigator-initiated Trials Highlight the Role of Sculptra® and Restylane® in Addressing Aesthetic Changes Associated With Weight Loss Medications and Menopause
Galderma (SIX: GALD), the pure-play dermatology category leader, today welcomes new data from two IITs, demonstrating the power of Sculptra - the first proven regenerative biostimulator - and the comp
April 08, 15:30
Variational AI Releases Enki 4: Major Update to Foundation Model for Small-Molecule Drug Discovery
Variational AI today announced the release of Enki™ 4, a major update to its generative AI platform for small-molecule drug discovery. The release of the fourth generation of Enki™ delivers significan
April 03, 13:30
VDYNE Receives FDA Approval to Initiate the TRIVITA[1] IDE Pivotal Trial of Transcatheter Tricuspid Valve Replacement System
VDYNE, Inc. (“VDYNE” or “the Company”), a privately held medical device company developing next generation transcatheter valve replacement technologies, today announced that the U.S. Food & Drug Admin
April 03, 11:30
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
Agenus (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.agenusbio.com&esheet=54475511&newsitemid=20260401039214&lan=en-US&anchor=Agenus&index=1&md5=543f2b7e0242fee88c23d833e5fff50
April 02, 14:30
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innova
WHOOP Raises $575 Million at $10.1 Billion Valuation to Advance Global Health Platform
April 02, 10:10
WHOOP Raises $575 Million at $10.1 Billion Valuation to Advance Global Health Platform
WHOOP (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.whoop.com%2Fus%2Fen%2F&esheet=54472286&newsitemid=20260331399622&lan=en-US&anchor=WHOOP%2C&index=1&md5=5b3c0a4ec1e7066bef07
HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics
March 31, 09:50
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)
HistoSonics (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhistosonics.com%2F&esheet=54465795&newsitemid=20260330349844&lan=en-US&anchor=HistoSonics&index=1&md5=83f0539aafc562f523a
March 31, 09:30
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innova
March 30, 09:30
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global an
March 29, 11:45
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
Takeda (TSE:4502/NYSE:TAK) today announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adult
March 29, 11:25
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clin
March 29, 10:25
Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innova
March 27, 12:00
Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging
Rubedo Life Sciences, Inc. (https://www.rubedolife.com/) (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targetin
March 27, 11:10
Invivoscribe® Expands IVDR Portfolio with IdentiClone® Dx IGH Assay Certification
Invivoscribe, a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to announce that its IdentiClone Dx IGH Assay has received In Vitro Diagnostic Regulation
March 26, 16:30
Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery
MindWave Innovations Inc., a Delaware corporation and wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (“APUS” or the “Company”) (NYSE American: APUS), today announced that on March 20, 202
The past 12 months have marked one of the most prolific periods of product innovation in Hyperice‘s
March 25, 15:50
Hyperice Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
Hyperice (https://hyperice.com/), a high-performance wellness brand, has been named to Fast Company’s (https://www.fastcompany.com/) prestigious list of the World’s Most Innovative Companies of 2026.
March 24, 16:39
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs
Galderma (SIX: GALD), the pure-play dermatology category leader, will present the latest updates on its innovations across its broad portfolio at the 2026 American Academy of Dermatology (AAD) Annual
Biocytogen Announces Strategic Collaboration with Moonlight Bio to Advance Cell Therapies Using Libr
March 24, 15:20
Biocytogen Announces Strategic Collaboration with Moonlight Bio to Advance Cell Therapies Using Library of Antibody Binders
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innova
March 23, 15:50
Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hollowing in patients over the age of 21.
March 20, 15:52
Galderma Publishes Invitation and Agenda for Its 2026 Annual General Meeting
Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today published the invitation and agenda for its 2026 Annual General Meeting (AGM), which will be held virtually on April 22,
Samsung Bioepis office in Songdo, Incheon, Republic of Korea
March 18, 16:38
Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates
Samsung Bioepis Co., Ltd. announced today that the company has entered into a global license, development and commercialization agreement (DCA) with Sandoz for up to five biosimilar candidates under d
March 18, 15:55
DNA Script Expands Global Access to On-demand DNA Synthesis With Distributor Agreements in Latin America and East Asia
DNA Script, a pioneer in DNA synthesis providing scientists with rapid, on-demand access to high-quality DNA, today announced it has signed distribution agreements with Gencell (https://cts.businesswi
March 17, 16:20
Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G Nfl Blood Assay
H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Europe N.V. has obtained a CE Certificate of the Lumipulse
March 17, 16:00
AMWC 2026: Galderma Showcases Category‑leading Innovation With a Comprehensive Portfolio and Holistic, Future‑focused Aesthetic Strategies
Galderma (SIX: GALD) will present nine abstracts at the Aesthetic & Anti‑Aging Medicine (AMWC) World Congress 2026 in Monaco, showcasing innovative and robust scientific data across its aesthetics por
25 per page50 per page75 per page100 per page